GENSIGHT BIOLOGICS news, videos and press releases - Page 2
For more news please use our advanced search feature.
GENSIGHT BIOLOGICS - More news...
GENSIGHT BIOLOGICS - More news...
- GenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business Update
- GenSight Biologics to Present at Upcoming Investor Conferences
- GenSight Biologics Secures €12 Million Financing Through a Premium Convertible Notes Issuance to an Institutional Investor and Provides Business Update
- GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy
- GenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals
- GenSight Biologics Secures a €35 Million Credit Facility From the European Investment Bank to Support the Launch of LUMEVOQ® in Europe
- GenSight Biologics Reports Cash Position and Revenues as of September 30, 2022
- GenSight Biologics to Present at Upcoming 2022 Medical Conferences
- GenSight Biologics to Present at Upcoming Industry and Investor Conferences
- GenSight Biologics Announces Successful Completion of LUMEVOQ® Engineering Batch Validating Implemented Corrective Actions
- GenSight Biologics Strengthens Its Management Team to Support the Launch of LUMEVOQ® in Europe
- GenSight Biologics Reports Interim Financial Results for the First Half of 2022
- GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®
- GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022
- GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
- GenSight Biologics: Annual General Meeting on May 25, 2022
- GenSight Biologics Announces the Filing of its 2021 Universal Registration Document
- GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022
- GenSight Biologics Granted Six-Month Extension in LUMEVOQ® European Regulatory Review
- GenSight Biologics Reports Full Year 2021 Consolidated Financial Results
- GenSight Biologics Provides Update on LUMEVOQ® Manufacturing Timeline
- GenSight Biologics Announces Its 2022 Financial Calendar
- GenSight Biologics to Present REFLECT Phase III Data with LUMEVOQ® at the NANOS 2022 Meeting
- GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of LUMEVOQ® in Europe
- GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
- GenSight Biologics Reports Cash Position as of December 31, 2021, and Provides Operational Update
- GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
- GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
- GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
- GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
